Annual Cash & Cash Equivalents
$2.49 B
-$241.80 M-8.86%
December 31, 2024
Summary
- As of February 18, 2025, REGN annual cash & cash equivalents is $2.49 billion, with the most recent change of -$241.80 million (-8.86%) on December 31, 2024.
- During the last 3 years, REGN annual cash & cash equivalents has fallen by -$397.40 million (-13.77%).
- REGN annual cash & cash equivalents is now -19.89% below its all-time high of $3.11 billion, reached on December 31, 2022.
Performance
REGN Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$2.49 B
+$476.40 M+23.68%
December 31, 2024
Summary
- As of February 18, 2025, REGN quarterly cash and cash equivalents is $2.49 billion, with the most recent change of +$476.40 million (+23.68%) on December 31, 2024.
- Over the past year, REGN quarterly cash and cash equivalents has dropped by -$241.80 million (-8.86%).
- REGN quarterly cash and cash equivalents is now -36.47% below its all-time high of $3.92 billion, reached on March 31, 2023.
Performance
REGN Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
REGN Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -8.9% | -8.9% |
| 3 y3 years | -13.8% | -8.9% |
| 5 y5 years | +53.8% | -8.9% |
REGN Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -19.9% | at low | -36.5% | +29.6% |
| 5 y | 5-year | -19.9% | +53.8% | -36.5% | +73.0% |
| alltime | all time | -19.9% | >+9999.0% | -36.5% | >+9999.0% |
Regeneron Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $2.49 B(-8.9%) | $2.49 B(+23.7%) |
| Sep 2024 | - | $2.01 B(+4.7%) |
| Jun 2024 | - | $1.92 B(-26.2%) |
| Mar 2024 | - | $2.60 B(-4.7%) |
| Dec 2023 | $2.73 B(-12.1%) | $2.73 B(+26.8%) |
| Sep 2023 | - | $2.15 B(+11.1%) |
| Jun 2023 | - | $1.94 B(-50.5%) |
| Mar 2023 | - | $3.92 B(+26.1%) |
| Dec 2022 | $3.11 B(+7.6%) | $3.11 B(-11.0%) |
| Sep 2022 | - | $3.49 B(+2.8%) |
| Jun 2022 | - | $3.40 B(+1.5%) |
| Mar 2022 | - | $3.35 B(+15.9%) |
| Dec 2021 | $2.89 B(+31.5%) | $2.89 B(-15.9%) |
| Sep 2021 | - | $3.43 B(+65.6%) |
| Jun 2021 | - | $2.07 B(+44.1%) |
| Mar 2021 | - | $1.44 B(-34.5%) |
| Dec 2020 | $2.19 B(+35.6%) | $2.19 B(+39.5%) |
| Sep 2020 | - | $1.57 B(-21.0%) |
| Jun 2020 | - | $1.99 B(-9.8%) |
| Mar 2020 | - | $2.21 B(+36.5%) |
| Dec 2019 | $1.62 B(+10.2%) | $1.62 B(+16.8%) |
| Sep 2019 | - | $1.38 B(+32.5%) |
| Jun 2019 | - | $1.05 B(-38.8%) |
| Mar 2019 | - | $1.71 B(+16.4%) |
| Dec 2018 | $1.47 B(+80.6%) | $1.47 B(+34.9%) |
| Sep 2018 | - | $1.09 B(+18.5%) |
| Jun 2018 | - | $917.88 M(-10.0%) |
| Mar 2018 | - | $1.02 B(+25.4%) |
| Dec 2017 | $812.70 M(+51.8%) | $812.70 M(+2.6%) |
| Sep 2017 | - | $792.07 M(+6.4%) |
| Jun 2017 | - | $744.31 M(-8.3%) |
| Mar 2017 | - | $811.77 M(+51.7%) |
| Dec 2016 | $535.20 M(-33.9%) | $535.20 M(-41.8%) |
| Sep 2016 | - | $920.36 M(+42.4%) |
| Jun 2016 | - | $646.51 M(+7.0%) |
| Mar 2016 | - | $604.21 M(-25.3%) |
| Dec 2015 | $809.10 M(+24.7%) | $809.10 M(+23.6%) |
| Sep 2015 | - | $654.59 M(+67.6%) |
| Jun 2015 | - | $390.55 M(-23.1%) |
| Mar 2015 | - | $507.91 M(-21.7%) |
| Dec 2014 | $648.72 M(+21.1%) | $648.72 M(+0.3%) |
| Sep 2014 | - | $646.55 M(+7.7%) |
| Jun 2014 | - | $600.13 M(+29.9%) |
| Mar 2014 | - | $461.86 M(-13.8%) |
| Dec 2013 | $535.61 M(+132.6%) | $535.61 M(+103.5%) |
| Sep 2013 | - | $263.21 M(-31.0%) |
| Jun 2013 | - | $381.68 M(+111.6%) |
| Mar 2013 | - | $180.36 M(-21.7%) |
| Dec 2012 | $230.28 M(-52.4%) | $230.28 M(+93.5%) |
| Sep 2012 | - | $119.00 M(-30.8%) |
| Jun 2012 | - | $171.94 M(-56.4%) |
| Mar 2012 | - | $394.58 M(-18.4%) |
| Dec 2011 | $483.61 M(+329.6%) | $483.61 M(+134.3%) |
| Sep 2011 | - | $206.40 M(-18.8%) |
| Jun 2011 | - | $254.31 M(+87.9%) |
| Mar 2011 | - | $135.38 M(+20.3%) |
| Dec 2010 | $112.57 M(-45.6%) | $112.57 M(-65.4%) |
| Sep 2010 | - | $325.29 M(+190.4%) |
| Jun 2010 | - | $112.00 M(-4.5%) |
| Mar 2010 | - | $117.31 M(-43.3%) |
| Dec 2009 | $207.07 M(-16.4%) | $207.07 M(-17.3%) |
| Sep 2009 | - | $250.32 M(-7.8%) |
| Jun 2009 | - | $271.47 M(+36.3%) |
| Mar 2009 | - | $199.10 M(-19.7%) |
| Dec 2008 | $247.80 M(-50.3%) | $247.80 M(-21.3%) |
| Sep 2008 | - | $314.68 M(+7.7%) |
| Jun 2008 | - | $292.13 M(-43.9%) |
| Mar 2008 | - | $520.88 M(+4.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2007 | $498.93 M(+109.7%) | $498.93 M(+412.2%) |
| Sep 2007 | - | $97.42 M(-11.2%) |
| Jun 2007 | - | $109.64 M(-29.9%) |
| Mar 2007 | - | $156.48 M(-34.2%) |
| Dec 2006 | $237.88 M(+28.9%) | $237.88 M(+41.9%) |
| Sep 2006 | - | $167.66 M(+45.8%) |
| Jun 2006 | - | $114.96 M(-37.0%) |
| Mar 2006 | - | $182.33 M(-1.2%) |
| Dec 2005 | $184.51 M(+93.8%) | $184.51 M(+4.8%) |
| Sep 2005 | - | $176.09 M(+21.3%) |
| Jun 2005 | - | $145.20 M(-1.8%) |
| Mar 2005 | - | $147.82 M(+55.2%) |
| Dec 2004 | $95.23 M(-19.5%) | $95.23 M(-9.3%) |
| Sep 2004 | - | $105.05 M(-14.5%) |
| Jun 2004 | - | $122.83 M(-29.4%) |
| Mar 2004 | - | $174.03 M(+47.1%) |
| Dec 2003 | $118.28 M(+47.7%) | $118.28 M(-60.4%) |
| Sep 2003 | - | $298.62 M(+130.3%) |
| Jun 2003 | - | $129.66 M(-32.3%) |
| Mar 2003 | - | $191.59 M(+139.3%) |
| Dec 2002 | $80.08 M(-67.6%) | $80.08 M(+6.0%) |
| Sep 2002 | - | $75.57 M(+8.9%) |
| Jun 2002 | - | $69.37 M(-48.8%) |
| Mar 2002 | - | $135.47 M(-45.2%) |
| Dec 2001 | $247.39 M(+698.6%) | $247.39 M(+147.5%) |
| Sep 2001 | - | $99.97 M(-30.1%) |
| Jun 2001 | - | $142.96 M(-22.1%) |
| Mar 2001 | - | $183.62 M(+492.7%) |
| Dec 2000 | $30.98 M(+30.7%) | $30.98 M(-37.6%) |
| Sep 2000 | - | $49.64 M(-39.3%) |
| Jun 2000 | - | $81.75 M(+565.0%) |
| Mar 2000 | - | $12.29 M(-48.1%) |
| Dec 1999 | $23.70 M(+19.7%) | $23.70 M(+0.9%) |
| Sep 1999 | - | $23.50 M(+14.1%) |
| Jun 1999 | - | $20.60 M(-5.5%) |
| Mar 1999 | - | $21.80 M(+10.1%) |
| Dec 1998 | $19.80 M(-31.5%) | $19.80 M(-12.4%) |
| Sep 1998 | - | $22.60 M(+0.4%) |
| Jun 1998 | - | $22.50 M(+16.6%) |
| Mar 1998 | - | $19.30 M(-33.2%) |
| Dec 1997 | $28.90 M(-16.2%) | $28.90 M(-28.3%) |
| Sep 1997 | - | $40.30 M(-21.6%) |
| Jun 1997 | - | $51.40 M(+84.2%) |
| Mar 1997 | - | $27.90 M(-19.1%) |
| Dec 1996 | $34.50 M(+5.5%) | $34.50 M(-8.0%) |
| Sep 1996 | - | $37.50 M(-23.3%) |
| Jun 1996 | - | $48.90 M(+310.9%) |
| Mar 1996 | - | $11.90 M(-63.6%) |
| Dec 1995 | $32.70 M(+38.6%) | $32.70 M(+454.2%) |
| Sep 1995 | - | $5.90 M(-64.9%) |
| Jun 1995 | - | $16.80 M(+32.3%) |
| Mar 1995 | - | $12.70 M(-46.2%) |
| Dec 1994 | $23.60 M(+88.8%) | $23.60 M(+54.2%) |
| Sep 1994 | - | $15.30 M(-15.0%) |
| Jun 1994 | - | $18.00 M(+125.0%) |
| Mar 1994 | - | $8.00 M(-36.0%) |
| Dec 1993 | $12.50 M(-23.8%) | $12.50 M(-68.5%) |
| Sep 1993 | - | $39.70 M(+402.5%) |
| Jun 1993 | - | $7.90 M(-21.8%) |
| Mar 1993 | - | $10.10 M(-38.4%) |
| Dec 1992 | $16.40 M(-37.4%) | $16.40 M(-14.6%) |
| Sep 1992 | - | $19.20 M(-12.7%) |
| Jun 1992 | - | $22.00 M(-11.6%) |
| Mar 1992 | - | $24.90 M(-5.0%) |
| Dec 1991 | $26.20 M(+20.2%) | $26.20 M(-25.1%) |
| Sep 1991 | - | $35.00 M(-10.7%) |
| Jun 1991 | - | $39.20 M(+79.8%) |
| Dec 1990 | $21.80 M | $21.80 M |
FAQ
- What is Regeneron Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Regeneron Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Regeneron Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of REGN is $2.49 B
What is the all time high annual cash & cash equivalents for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual cash & cash equivalents is $3.11 B
What is Regeneron Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, REGN annual cash & cash equivalents has changed by -$241.80 M (-8.86%)
What is Regeneron Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of REGN is $2.49 B
What is the all time high quarterly cash and cash equivalents for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly cash and cash equivalents is $3.92 B
What is Regeneron Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, REGN quarterly cash and cash equivalents has changed by -$241.80 M (-8.86%)